User menu

Treatment of Advanced Dermatofibrosarcoma Protuberans (DFSP) with Imatinib Mesylate and with or without Surgical Resection

Bibliographic reference Rutkowski, P. ; Debiec-Rychter, Maria ; Nowecki, Z. I. ; Zdzienicki, M. ; Ruka, W.. Treatment of Advanced Dermatofibrosarcoma Protuberans (DFSP) with Imatinib Mesylate and with or without Surgical Resection.63rd Annual Cancer Symposium of the Society-of-Surgical-Oncology (St Louis(Mo), Mar 03-07, 2010). In: Annals of Surgical Oncology, Vol. 17, p. S31 (2010)
Permanent URL
  1. Osborne NH, Wakefiled TW, Henke PK. Venous thromboembolism in cancer patients undergoing major surgery. Ann Surg Oncol. 2008;15:3567–78.
  2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:381S–453S.
  3. Khushal A, Quinlan D, Alikhan R, et al. Thromboembolic disease in surgery for malignancy—rationale for prolonged thromboprophylaxis. Semin Thromb Hemost. 2002;28:569–76.
  4. Rasmussen MS. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis. Cancer Treat Rev. 2002;28:141–4.
  5. Bergqvist D, Agnelli G, Cohen AT, et al. for the ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975–80.
  6. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, et al. for the FAME investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006;4:2384–90.
  7. Lausen I, Jensen R, Jorgense LN, et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg. 1998;164:657–63.
  8. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS Project. Ann Surg. 2006;243:89–95.
  9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Venous thromboembolic disease, v.2.2008. . Accessed 23 August 2009.
  10. Layman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490–505.
  11. Stratton MA, Anderson FA, Bussey HI. Prevention of venous thromboembolism. Adherence to the 1995 American College of Chest Physicians Consensus Guidelines for Surgical Patients. Arch Intern Med. 2000;160:334–40.
  12. Kakkar AK, Levine M, Piedo HM, Wolfe R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003;8:381–8.
  13. Wolff RA. Are patients with cancer receiving adequate thromboprophylaxis? Results from FRONTLINE. Cancer Treat Rev. 2003;29:7–9.
  14. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest. 2001;120:1964–71.
  15. Amin A, Stemkowski S, Lin J, Yang G. Appropriate thromboprophylaxis in hospitalized cancer patients. Clin Adv Hematol Oncol. 2008;6:910–20.
  16. Mismetti P, Leporte S, Darmon JT, et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001;88:913–30.
  17. Manganelli D, Paxxagli M, Mazzantini D, et al. Prolonged prophylaxis with unfractionated heparin is effective to reduce delayed deep vein thrombosis in total hip replacement. Respiration. 1998;65:369–74.
  18. Bennett CL, Yarnold PR, Evens AM, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006;296:2558–60.
  19. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295–302.
  20. Warkentin TE, Kelton JG. A 14-year study of heparin-induce thrombocytopenia. Am J Med. 1996;101:502–7.
  21. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–5.
  22. Comp Philip C., Spiro Theodore E., Friedman Richard J., Whitsett Thomas L., Johnson Gerhard J., Gardiner Geoffrey A., Landon Glenn C., Jové Maurice, Prolonged Enoxaparin Therapy to Prevent Venous Thromboembolism After Primary Hip or Knee Replacement : , 10.2106/00004623-200103000-00004
  23. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996;348:224–8.
  24. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery—results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin®). Thromb Haemost. 1997;77:26–31.
  25. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (Enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996;335:696–700.
  26. Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty—the Danish Prolonged Prophylaxis (DaPP) study. Thromb Res. 1998;89:281–7.
  27. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients. Arch Intern Med. 2000;160:2208–15.
  28. Heit John A., Elliott C. Gregory, Trowbridge Arthur A., Morrey Bernard F., Gent Michael, Hirsh Jack, , Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement : A Randomized, Double-Blind, Placebo-Controlled Trial, 10.7326/0003-4819-132-11-200006060-00002
  29. Martel N, Lee J, Wells PS. Risk for Heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106:2710–5.
  30. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.
  31. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.
  32. Red Book. Montvale, NJ: Thompson, 2006.
  33. Centers for Medicare and Medicaid Services. Medicare provider analysis and review database. . Accessed 23 August 2009.
  34. Muennig P, Khan K. Designing and conducting cost-effectiveness analyses in medicine and health care. San Francisco: Jossey-Bass, 2002.
  35. Centers for Medicare and Medicaid Services. Medicare hospital outpatient prospective payment system. . Accessed 23 August 2009.
  36. National Cancer Databank. Patterns of diagnosis and treatment for selected cancers, 2006. . Accessed 23 August 2009.
  37. Sarasin François P., Cost-effectiveness of Prophylactic Anticoagulation Prolonged After Hospital Discharge Following General Surgery, 10.1001/archsurg.1996.01430190016003
  38. Hovens MMC, Snoep JD, Tamsma JT, Huisman MV. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost. 2006;4:1470–5.
  39. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:338S–400S.